These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 27006265

  • 1. Osteomalacia by a mesenchymal-FGF23-producing tumour: Successful treatment with radiofrequency ablation. A case report.
    Igney-Oertel A, Artunc F, Henes J, Hoffmann R, Clasen S.
    Joint Bone Spine; 2016 Oct; 83(5):603-4. PubMed ID: 27006265
    [No Abstract] [Full Text] [Related]

  • 2. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
    Hannan FM, Athanasou NA, Teh J, Gibbons CL, Shine B, Thakker RV.
    Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
    [Abstract] [Full Text] [Related]

  • 3. Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report.
    Ryhänen EM, Schalin-Jäntti C, Matikainen N.
    Front Endocrinol (Lausanne); 2021 Feb; 12():686135. PubMed ID: 34149623
    [Abstract] [Full Text] [Related]

  • 4. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R, Onodera T, Terkawi MA, Mitsuhashi T, Kondo E, Iwasaki N.
    BMC Musculoskelet Disord; 2017 Feb 13; 18(1):79. PubMed ID: 28193220
    [Abstract] [Full Text] [Related]

  • 5. Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma.
    Elderman JH, Wabbijn M, de Jongh F.
    BMJ Case Rep; 2016 Apr 26; 2016():. PubMed ID: 27118742
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.
    Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T.
    J Intern Med; 2010 Oct 26; 268(4):390-4. PubMed ID: 20698924
    [No Abstract] [Full Text] [Related]

  • 7. Tumour-induced osteomalacia: the long road to diagnosis and recovery.
    Vollmer S, Olsson K.
    BMJ Case Rep; 2024 May 02; 17(5):. PubMed ID: 38697682
    [Abstract] [Full Text] [Related]

  • 8. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.
    Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K.
    Intern Med; 2008 May 02; 47(10):957-61. PubMed ID: 18480582
    [Abstract] [Full Text] [Related]

  • 9. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
    Ovejero D, El-Maouche D, Brillante BA, Khosravi A, Gafni RI, Collins MT.
    J Bone Miner Res; 2017 Aug 02; 32(8):1667-1671. PubMed ID: 28459498
    [Abstract] [Full Text] [Related]

  • 10. Tumour-induced osteomalacia.
    Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, Collins MT.
    Nat Rev Dis Primers; 2017 Jul 13; 3():17044. PubMed ID: 28703220
    [Abstract] [Full Text] [Related]

  • 11. Determination of the elimination half-life of fibroblast growth factor-23.
    Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT.
    J Clin Endocrinol Metab; 2007 Jun 13; 92(6):2374-7. PubMed ID: 17374707
    [Abstract] [Full Text] [Related]

  • 12. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels].
    de Jongh RT, Vervloet MG, Bravenboer N, Heijboer AC, den Heijer M, Lips P.
    Ned Tijdschr Geneeskd; 2013 Jun 13; 157(28):A5908. PubMed ID: 23841927
    [Abstract] [Full Text] [Related]

  • 13. Tumor induced osteomalacia from a peripheral mesenchymal tumour of the foot.
    Strydom A, Greeff W, Ferrao PNF, Saragas NP.
    Foot (Edinb); 2023 May 13; 55():101979. PubMed ID: 36871520
    [Abstract] [Full Text] [Related]

  • 14. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
    Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J, You YH, Liu BY, Cui AM, Deng W.
    BMC Musculoskelet Disord; 2017 Sep 21; 18(1):403. PubMed ID: 28934935
    [Abstract] [Full Text] [Related]

  • 15. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
    Higley M, Beckett B, Schmahmann S, Dacey E, Foss E.
    Skeletal Radiol; 2015 Dec 21; 44(12):1825-31. PubMed ID: 26341245
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
    Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ.
    J Clin Endocrinol Metab; 2006 Jun 21; 91(6):2055-61. PubMed ID: 16551733
    [Abstract] [Full Text] [Related]

  • 17. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T.
    Clin Calcium; 2013 Oct 21; 23(10):1429-35. PubMed ID: 24076640
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic osteomalacia.
    Sundaram M, McCarthy EF.
    Skeletal Radiol; 2000 Mar 21; 29(3):117-24. PubMed ID: 10794548
    [No Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Fukumoto S, Yamashita T.
    N Engl J Med; 2003 Jul 31; 349(5):505-6; author reply 505-6. PubMed ID: 12892105
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.